|show morePrint Bio
John C. Lechleiter, Ph.D.
Chairman, President, and Chief Executive Officer
(Currently on medical leave)
John C. Lechleiter, Ph.D., has served as president and chief executive officer of Eli Lilly and Company since April 1, 2008. He became chairman of the board of directors on January 1, 2009.
Lechleiter joined Lilly in 1979 as a senior organic chemist in process research and development and became head of that department in 1982. In 1984, he began serving as director of pharmaceutical product development for the Lilly Research Centre Limited in Windlesham, England.
He returned to the United States in 1986 as manager of research and development projects for Europe. In 1988, he became director of development projects management, and he assumed additional responsibility for pharmaceutical regulatory affairs the following year. In 1991, Lechleiter was named executive director of pharmaceutical product development, and he became vice president in 1993. He was appointed vice president of regulatory affairs in 1994, was named vice president for development and regulatory affairs in 1996, and became senior vice president of pharmaceutical products in 1998.
In 2001, Lechleiter was appointed executive vice president for pharmaceutical products and corporate development. In 2004, he became Lilly’s executive vice president for pharmaceutical operations. And in 2005, he was named president and chief operating officer and joined the board of directors.
Lechleiter received a bachelor of science degree in chemistry from Xavier University (Cincinnati, Ohio) in 1975. He subsequently studied organic chemistry as a National Science Foundation Fellow at Harvard University, where he received his master’s and doctorate degrees in 1980. Lechleiter has received honorary doctorates from Marian University (Indianapolis, Indiana), the University of Indianapolis, and the National University of Ireland.
Lechleiter is a member of the American Chemical Society and Business Roundtable. Dr. Lechleiter serves on the board of the Pharmaceutical Research and Manufacturers of America (PhRMA), as president of the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA), and on the boards of United Way Worldwide, Xavier University (Cincinnati, Ohio), the Life Sciences Foundation, and the Central Indiana Corporate Partnership. He also serves on the board of Nike, Inc.
show morePrint Bio
Derica W. Rice
Acting Chief Executive Officer
Executive Vice President, Global Services, and Chief Financial Officer
Derica W. Rice was promoted to executive vice president, global services and chief financial officer, effective January 1, 2010. As of May 13, 2013, he is serving as Acting Chief Executive Officer. He also is a member of the company’s executive committee. Prior to becoming Lilly’s CFO in 2006, Rice had been the vice president and controller since July 2003.
Born in Decatur, Alabama, he received a bachelor's degree in electrical engineering from Kettering University (formerly the GMI Engineering & Management Institute) in 1988 and a master's degree in business administration in 1990 from Indiana University.
Rice joined the company in 1990 as an international treasury associate. He held various assignments as a sales representative, manager of global financial planning and analysis for the medical devices division, and global planning manager for pharmaceuticals. In 1995, he became finance director and chief financial officer for Lilly Canada. In 1997, Rice was promoted to executive director and chief financial officer for European operations based in London. In 2000, he was the general manager of Lilly United Kingdom and Republic of Ireland.
In 2009, Rice was selected as one of the “Most Powerful Executives in Corporate America” by Black Enterprise magazine and he was selected as one of Diversity MBA magazine’s “Top 100 Under 50 Executives.” He serves as a member of the Board of Directors for Target Corporation, IU Health North and The Center for Leadership Development. He also serves as a member of the Indiana University Board of Trustees and the Board of Governors of the Indianapolis Museum of Art.
show morePrint Bio
Melissa S Barnes
Chief Ethics and Compliance Officer and Senior Vice President, Enterprise Risk Management
Melissa Stapleton Barnes became chief ethics and compliance officer and senior vice president, enterprise risk management, for Eli Lilly and Company in January 2013 and is a member of the company’s executive committee.
Prior to taking this position, Ms. Barnes held a variety of business and legal roles. She served as general counsel for Lilly Diabetes and Lilly Oncology, both global business units responsible for development and commercialization of Lilly products worldwide. She also counseled on all antitrust matters, as well as global marketing and sales, managed market/business-to-business, and pricing matters. Notably, she spent two years as a dedicated Six Sigma Black Belt responsible for leading quality/productivity enhancing projects in Lilly Legal. She also serves on the executive team of the Lilly Women’s Network and chairs the External Connectivity Committee.
Prior to joining Lilly, Ms. Barnes handled complex antitrust litigation at Baker & Daniels and was a Research Assistant to Phillip E. Areeda in his drafting of Antitrust Law, Volume IX.
Born in Noblesville, Indiana, she received a Bachelor of Science degree with highest distinction from Purdue University and received a Juris Doctorate from Harvard Law School.
Other professional and community activities include Board of Directors for The Center for the Performing Arts; advisory board member and frequent speaker for the American Conference Institute; advisory board member for Integrating Women Leaders, Inc.; and formerly on the Board of Directors for Indiana Medical Device Manufacturers Council, Inc. (2009-2010). Ms. Barnes is also an active member of the Carmel Young Life Leadership Committee, as well as Pleasant View Baptist Church.
show morePrint Bio
Senior Vice President and President, Lilly Diabetes
Enrique Conterno became president of Lilly Diabetes on November 1, 2009. With a heritage extending back to nearly 90 years ago when Lilly introduced the world’s first commercial insulin, Lilly Diabetes continues working to meet the diverse needs of people with diabetes. The business, which became operational in January 2010, features a growing portfolio of products representing the most important therapeutic areas of diabetes care.
Conterno is also a senior vice president for Eli Lilly and Company. Since January 2009, he had served as president of Lilly USA. He is a member of Lilly's executive committee.
Born in Lima, Peru, Conterno earned a master's of business administration degree at Duke University in 1992. He earned his bachelor’s degree in mechanical engineering from Case Western Reserve University in 1989.
Conterno joined Lilly as a sales representative in 1992. From 1993 to 1995, he held roles as a financial analyst, marketing associate, and business development manager. In 1996, Conterno became sales and marketing director for the Peru affiliate, and in 1998, he became the sales and marketing director for Lilly's affiliate in Brazil. In 2000, Conterno was named executive director of marketing for the intercontinental region and Japan.
Conterno served as president and general manager for Lilly’s operations in Mexico in 2003, leading one of the company’s largest affiliates outside the U.S. In July 2006, he was named vice president of Lilly USA's neuroscience business unit, and in June 2008, he became senior vice president for health care professional markets for Lilly USA.
show morePrint Bio
President, Manufacturing Operations
Maria Crowe became president of global manufacturing operations on January 1, 2012, leading a global network of 23 sites in 13 countries. She also has responsibility for Lilly's global contract-manufacturing organization.
In her previous role as senior vice president for global drug product manufacturing, a post she held since August 2009, Crowe oversaw drug-product manufacturing, packaging, and distribution operations in 11 countries. This included sites that manufacture tablets and capsules as well as those that manufacture injectable products formulated into vials, injection pens, and other delivery methods. Crowe also was responsible for emerging markets manufacturing, external drug-product operations, and U.S. distribution.
From 2007-2009, Crowe was vice president for drug product manufacturing in the Americas (the United States and Latin America). She previously was general manager at Lilly's Kinsale, Ireland, plant for two years, general manager of Lilly del Caribe in Puerto Rico for five years, and plant manager of Lilly's Elanco manufacturing plant at the former Tippecanoe site for one year. In her 29-year Lilly career, Crowe has held numerous roles in dry products, parenteral products, and API manufacturing, as well as in sourcing and procurement.
Crowe's business-management experience includes responsibilities for the start-up of two new Lilly sites in Puerto Rico, as well as planning for the new biotech operation at Kinsale.
Crowe holds a bachelor's degree in industrial management (with a minor in computer science) from Purdue University in West Lafayette, Indiana. She is a member of Purdue's Krannert School of Management Dean's Advisory Council, and she sits on the advisory board of Purdue's Global Policy Research Institute.
show morePrint Bio
Stephen F. Fry
Senior Vice President, Human Resources and Diversity
Steve Fry became senior vice president, human resources and diversity, for Eli Lilly and Company in March 2011. He is also a member of the executive committee. He has served as vice president, human resources, for Eli Lilly and Company since February 2007.
Fry earned a bachelor of science degree in information systems from the University of Indianapolis. He joined Lilly in 1987 as a scientific systems analyst in Lilly Research Laboratories.
After a series of managerial assignments in IT and HR, Fry became the human resource director for Lilly’s United Kingdom affiliate in 1998. Following this assignment, he served as the executive director of human resources for the U.S. affiliate in 1999. He was the managing director for the Australian affiliate from 2004 to 2007. He returned to the U.S. in 2007 and provided HR leadership for the global sales and marketing organization before accepting the role of vice president supporting the Lilly bio-medicines and emerging markets business units.
Fry has been instrumental in Lilly’s efforts to re-organize into business units and transform the way the company provides human resource services to the business.
His extensive HR background, coupled with a strong business orientation, helps him lead the human resource organization with a vision that is grounded in the company’s commitment to provide better patient outcomes.
Fry serves on the Board of Trustees, University of Indianapolis and Make A Wish Ohio, Kentucky and Indiana’s Governance Board of Directors. He has two children.
show morePrint Bio
Michael J. Harrington
Senior Vice President and General Counsel
Michael J. Harrington became senior vice president and general counsel for Eli Lilly and Company in January 2013 and is a member of the company’s executive committee.
Prior to taking this position, Mike served as vice president and deputy general counsel, global pharmaceutical operations. In this capacity, he was responsible for legal issues related to Eli Lilly and Company’s five global business units (Animal Health, Bio-Medicines, Diabetes, Emerging Markets and Oncology). Since joining Lilly in 1991 as an attorney in product liability litigation, Mike has served in a number of other business and legal positions with Lilly including managing director of Eli Lilly New Zealand and as general counsel for Lilly’s operations in the Asia Pacific region.
Born in Evanston, Illinois, Mike received his Bachelor of Arts degree in English in 1985 from Albion College. He received his law degree from the Columbia University School of Law in 1988. Prior to joining Lilly, Mike was a litigator at the law firm of Baker & Daniels in Indianapolis.
Mike currently serves on the boards and executive committees of the Indiana Chamber of Commerce, Lawyers for Civil Justice and the Indiana Repertory Theatre. He is also a member of the board of trustees of Albion College and a member of the board of the International School of Indiana.
show morePrint Bio
Jan M. Lundberg, Ph.D
Executive Vice President, Science and Technology, and
President, Lilly Research Laboratories
Jan M. Lundberg, Ph.D. is Executive Vice President for Science and Technology and President of Lilly Research Laboratories (LRL). He is also a member of the company’s executive committee.
Dr. Lundberg joined Eli Lilly and Company January, 2010, with responsibility for Research and the Development Center of Excellence at Lilly. Prior to assuming his position at Lilly, Dr. Lundberg served as Global Head of Discovery Research at AstraZeneca for ten years and was a member of the senior executive team. He was involved with numerous candidate drug nominations, development projects and support for marketed products.
After his medical education and receiving his Ph.D., Dr. Lundberg served as Professor at the Department of Pharmacology, Karolinska Institute, Stockholm, Sweden. Dr. Lundberg has authored over 500 publications of original articles in international peer-reviewed journals and is listed as one of the highly cited authors by the Institute for Scientific Information (ISI). His work has focused on cell signaling in integrated systems using multiple mediators (peptides, purines, and nitric oxide) with translational applications to nervous system, endocrine, inflammation and cardiovascular areas. This research has been highly recognized and has received several awards. He has also been appointed as Honorary Doctor at the Pharmaceutical Faculty, Uppsala University (2006).
Dr. Lundberg is the co-founder of a biotech diagnostic company (Aerocrine AB).
Dr. Lundberg has served on several committees which include Chairman, PhD and post doc programme at the Karolinska Institute, Evaluation Committee for the Swedish Medical Research Council, Executive Advisory Board, the Swedish Medical Products Agency Registration of New Drugs (part of EMEA), and EFPIA Research head group generating the Innovative Medicines Initiative (IMI), a major public private partnership with the European Union. He serves on PhRMA’s Science and Regulatory Committee and is on the board of Biotechnology Industry Organization (BIO) and BioCrossroads.
show morePrint Bio
Sue Mahony, Ph.D
Senior Vice President and President, Lilly Oncology
Sue Mahony, Ph.D., became president of Lilly Oncology in March 2011. She is also a senior vice president for Eli Lilly and Company and a member of the company’s executive committee.
In May 2009, she was appointed senior vice president, human resources and diversity for Lilly. Previously, she led Lilly’s operations in Canada.
Mahony was born and educated in the United Kingdom, where she obtained a bachelor of science degree in pharmacy from Aston University in Great Britain. She obtained her Ph.D. in pharmacy in 1989 in the Cancer Research Campaign Experimental Chemotherapy Group also at Aston University. She then received a master’s degree in business administration in 1998 from the London School of Business.
Mahony joined Lilly in 2000 after more than a decade in sales and marketing roles in the United Kingdom and Europe in oncology/hematology and cardiovascular medicine for Schering-Plough, Amgen and Bristol-Myers Squibb. Since joining Lilly, Mahony has held roles in global marketing, product development, Six Sigma and general management, including global brand development leader for duloxetine (Cymbalta®) and fluoxetine (Prozac®).
In 2010, Mahony was recognized as one of the Indianapolis Business Journal’s “Women of Influence.” Mahony has served on the board of the United Way of Central Indiana since 2010.
show morePrint Bio
Senior Vice President, Corporate Affairs and Communications
Bart Peterson joined Eli Lilly and Company in June 2009 as senior vice president of corporate affairs and communications. He is a member of the company’s executive committee.
Peterson received a bachelor’s degree from Purdue University in 1980 and earned his law degree at the University of Michigan in 1983.
Prior to joining Lilly, Peterson was Managing Director at Strategic Capital Partners, LLC from June 2008 to June 2009. During spring 2008, Peterson was a fellow with the Institute of Politics of Harvard University’s Kennedy School of Government. During the 2008-2009 school year, Peterson was a Distinguished Visiting Professor of Public Policy at Ball State University. He continues as a fellow with the University’s Bowen Center for Public Affairs.
From 2000 to 2007, Peterson served two terms as Mayor of Indianapolis, the nation’s 12th largest city. He also served as President of the National League of Cities in 2007. As mayor, Peterson led a transformation of public education in Indianapolis as the only mayor in America with the authority to create new schools by issuing charters. He was responsible for 16 charter schools and won Harvard University’s prestigious Innovations in American Government Award for the initiative in 2006. He was also instrumental in the business expansions of FedEx, Rolls Royce, and WellPoint in Indianapolis, and the construction and development of major projects such as Lucas Oil Stadium, the Conrad Indianapolis, Simon Property Group’s world headquarters, the new Indianapolis International Airport’s Col. H. Weir Cook terminal building, and the future Indiana Convention Center expansion and J.W. Marriott Hotel.
Along with Indiana University, Purdue University, Lilly, and the Central Indiana Corporate Partnership, he created BioCrossroads, a focused effort to push Indianapolis to the forefront as a life sciences capital. Peterson was honored by the National Association of Clean Water Agencies with their city government leader of the year award for his efforts in cleaning up the Indianapolis waterways.
Prior to running for office, Peterson served as a member of Indiana Governor Evan Bayh’s leadership team, first as his aide for environmental affairs and later as chief of staff, and was an attorney with IceMiller, an Indianapolis law firm.
Peterson is a founding member and board chair of The Mind Trust, a non-profit organization promoting entrepreneurship in education. He is also a board member of the Regenstrief Foundation and the Christian Theological Seminary, as well as a member of the Board of Advisors for Ball State University’s Bowen Center for Public Affairs. In 2012, Peterson was appointed by the US State Department to the Asia-Pacific Economic Cooperation (APEC) Business Advisory Council.
show morePrint Bio
Senior Vice President and President, Lilly Bio-Medicines
Dave Ricks became senior vice president and president of Lilly Bio-Medicines in January 2012. Bio-Medicines is the largest of Lilly’s five business areas in terms of sales and includes more than 20 countries, among them the world’s largest pharmaceutical markets, including the U.S.and Japan, along with Lilly’s ACE region (Australia, Canada, and Europe). He is also a senior vice president for Eli Lilly and Company and is a member of the company’s executive committee,
Bio-Medicines encompasses the therapeutic areas of neuroscience, cardiovascular, urology, musculoskeletal and autoimmunity. Bio-Medicines is also home to Lilly’s global marketing organization and Lilly’s PRA (pricing, reimbursement, and access) function.
Ricks joined Lilly in 1996 as a business development associate and held several management roles in U.S. marketing and sales before moving to Lilly Canada in 2002 as director of pharmaceutical marketing and then national sales director in 2004. From 2005 to 2008, Ricks was general manager of Lilly Canada. He served as president and general manager of Lilly China, one of the world’s fastest-growing emerging markets, from 2008 to 2009, before becoming president of Lilly USA in 2009.
Ricks earned a bachelor’s degree in business from Purdue University in 1990, and an MBA from Indiana University in 1996. He has also worked for Hewlett Packard Corporation and IBM.
show morePrint Bio
Senior Vice President and President, Elanco Animal Health
Since 2008, Jeff Simmons has served as president of Elanco, the animal health division of Eli Lilly and Company. As part of this role, he also serves as a Senior Vice-President and Executive Officer of Lilly. Elanco is an innovation-driven company with offices in more than 75 countries. In more than two decades with the company, Simmons has held a number of sales, marketing and management positions, in the United States and abroad, including serving as country director in Brazil and area director for West Europe based in the U.K.
These international experiences offered Simmons a new perspective on food and agriculture and created a deep conviction about the need for solutions to global hunger. Elanco is bringing this vision to life via a commitment to end hunger for 100,000 families globally, and to creating a hunger-free community for children surrounding its central Indiana headquarters. Simmons has become an active advocate for the role technology plays in sustainable, efficient production of safe, affordable meat, dairy and eggs. He has published two white papers on this topic, available at Plenty to Think About website.
Simmons also holds a number of leadership positions, including serving on the board of directors for Chiquita, Gleaners Food Bank of Central Indiana and the International Federation of Animal Health (IFAH). He is also a member of Harvard’s Private and Public, Scientific, Academic and Consumer Food Policy Group (PAPSAC) committee.
show morePrint Bio
Senior Vice President and President, Emerging Markets
Jacques Tapiero became president of emerging markets on November 1, 2009. The business unit, which became operational on January 1, 2010, increases the company's focus on many of the world's fastest-growing markets, such as China, Russia, Brazil, Mexico, South Korea, and Turkey. Tapiero is also a senior vice president for Eli Lilly and Company. Since November 2004, he had served as president of the intercontinental region for Lilly, which comprised offices in Asia, Australia, Africa and Middle East Countries, Canada, Latin America and Russia. He is a member of the company’s executive committee.
Born in Morocco, Tapiero is a Swiss citizen who in 1980 received a master of business administration from the Ecole Superieure de Commerce at Clermond Ferrand in France. In 1982, he obtained a second master of business administration degree at the American Graduate School of International Management in Glendale, Arizona.
Tapiero joined Lilly in 1983 as a financial analyst. He held several sales and finance positions at Indianapolis, France, Sweden, and Switzerland. He was named managing director of Lilly Sweden in 1993. From 1995 to 1999, Tapiero was president and general manager at Lilly Brazil. In late 1999, Tapiero was named president and general manager for Lilly France.
Tapiero is a member of the Thunderbird Global Council, a council of leading business executives who advise Thunderbird, the School of Global Management, a leader in global business education. Tapiero also serves on the board of directors for McCormick & Company, a global leader in flavor.
show morePrint Bio
Fionnuala M. Walsh
Senior Vice President, Global Quality
Fionnuala M. Walsh, Ph.D., became senior vice president of global quality for Eli Lilly and Company in July 2007 and is a member of Lilly's executive committee. She had been vice president for global quality operations since 2005 and global quality leader since 2002. Walsh reports directly to John Lechleiter, Ph.D., Lilly chairman, president, and CEO, and she is a member of the manufacturing policy committee.
Born in Ireland, Walsh received her bachelor and doctorate degrees in chemistry from University College, Dublin. She joined Lilly in 1988 at the manufacturing site in Kinsale, Ireland, following an industrial post-doctorate fellowship in Puerto Rico.
At the Kinsale site, Walsh held roles in technical services (1988), leader of outsourcing projects (1990), new-product introduction (1994), and leader of the analytical laboratory (1995). She held management positions at Kinsale in quality, regulatory, and manufacturing science and technology.
Walsh has served as a member of the Irish Council for Science, Technology, and Innovation and the PhRMA API Committee.